Europe Graft-Versus-Host Disease GVHD Treatment Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	272 Pages	Data Bridge Market Research	April, 2024	DAABD18813137

Best Price Guarantee
Price	from $3,500
Length	272 Pages
Publisher	Data Bridge Market Research
Published Date	April, 2024
SKU	DAABD18813137

Europe Graft-Versus-Host Disease GVHD Treatment Market

Europe Graft-Versus-Host Disease (GVHD) treatment market is expected to reach USD 1,353,911.07 thousand by 2031, from USD 980,666.00 thousand in 2023 growing at the CAGR of 4.2% in the forecast period of 2024 to 2031.
Market Segmentation:
Europe Graft-Versus-Host Disease (GVHD) Treatment Market, By Treatment (Medication and Therapy), Type (Chronic GVHD, Acute GVHD, and Prophylactic), Gender (Female and Male), Age (Adults and Pediatric), Method of Administration (Oral, Intravenous, Topical, and Others), End User (Hospitals, Transplant Centers, Institutes and Specialty Centers), Distribution Channel (Direct Tender, Retail Sales and Others), By Country (Germany, France, Italy, U.K., Spain, Belgium, Russia, Switzerland, Denmark, Rest of Europe)– Industry Trends and Forecast to 2031
Overview of Europe Graft-Versus-Host Disease (GVHD) Treatment Market Dynamics:

Drivers
• Increasing incidence of hematopoietic stem cell transplants (HSCT)
• Awareness campaigns and patient education
• Advancements in treatment options

Restraints
• High cost of medications and supportive care
• Disease heterogeneity

Opportunities
• Market expansion through strategic initiatives and partnership
• Growing pipeline of innovative drugs for GVHD treatment
• Empowering patient centric approach to GVHD treatment
Challenges
• Stringent regulations in GVHD therapies
• Safety concerns and complexities during treatment

Market Players

The key market players for Europe Graft-Versus-Host Disease (GVHD) treatment market are listed below:
• Bristol-Myers Squibb Company
• AbbVie Inc
• Novartis AG
• Janssen Global Services, LLC
• Mallinckrodt
• Incyte
• Sanofi
• Alkem Laboratories Ltd
• Astellas Pharma Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of The Europe Graft-versus-host Disease (Gvhd) Treatment Market; 1.4 Currency And Pricing; 1.5 Limitations; 1.6 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Geographical Scope; 2.3 Years Considered For The Study; 2.4 DBMR Tripod Data Validation Model; 2.5 Primary Interviews With Key Opinion Leaders; 2.6 Multivariate Modelling; 2.7 Market Application Coverage Grid; 2.8 DBMR Market Position Grid; 2.9 Vendor Share Analysis; 2.10 Secondary Sources; 2.11 Assumptions
3 Executive Summary
4 Premium Insights: 4.1 Pestel Analysis_; 4.2 Porter's Five Forces Model
5 Pipe Line Analysis Of Graft Versus Host Disease Market
6 Regulation
7 Market Overview: 7.1 Drivers; 7.1.1 Increasing Incidence Of Hematopoietic Stem Cell Transplants (Hsct); 7.1.2 Awareness Campaigns And Patient Education; 7.1.3 Advancements In Treatment Options; 7.2 Restraints; 7.2.1 High Cost Of Medications And Supportive Care; 7.2.2 Disease Heterogeneity; 7.3 Opportunities; 7.3.1 Market Expansion Through Strategic Initiatives And Partnership; 7.3.2 Growing Pipeline Of Innovative Drugs For Gvhd Treatment; 7.3.3 Empowering Patient-centric Approach To Gvhd Treatment; 7.4 Challenges; 7.4.1 Stringent Regulations In Gvhd Therapies; 7.4.2 Safety Concern And Complexities During Treatment
8 Europe Graft-versus-host-disease (Gvhd) Treatment Market, By Type: 8.1 Overview; 8.2 Chronic Gvhd; 8.2.1 Corticosteroids; 8.2.1.1 Prednisolone; 8.2.1.2 Methylprednisolone; 8.2.2 Immunosuppressive; 8.2.2.1 Mycophenolate Mofetil (Mmf); 8.2.2.2 Methotrexate (Mtx); 8.2.2.3 Ibrutinib; 8.2.2.4 Belumosudil; 8.2.2.5 Ruxolitinib; 8.2.2.6 Antithymocyte Globulin (Atg); 8.2.2.7 Others; 8.2.3 Calcineurin Inhibitors; 8.2.4 Others; 8.2.4.1 Branded; 8.2.4.1.1 Rezurock; 8.2.4.1.2 Imbruvica; 8.2.4.1.3 Jakafi; 8.2.4.2 Generic; 8.3 Acute Gvhd; 8.3.1 Corticosteroids; 8.3.1.1 Methylprednisolone; 8.3.1.2 Prednisolone; 8.3.2 Immunosuppressive; 8.3.2.1 Mycophenolate Mofetil (Mmf); 8.3.2.2 Ruxolitinib; 8.3.2.3 Others; 8.3.3 Calcineurin Inhibitors; 8.3.3.1 Tacrolimus (Tac); 8.3.3.2 Cyclosporin (Csa); 8.3.4 Others; 8.4 Prophylactic; 8.4.1 Cyclosporin (Csa); 8.4.2 Methotrexate (Mtx); 8.4.3 Tacrolimus (Tac); 8.4.4 Methylprednisolone; 8.4.5 Others; 8.4.5.1 Generic; 8.4.5.2 Branded; 8.4.5.2.1 Orencia; 8.4.5.2.2 Others
9 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Method Of Administration: 9.1 Overview; 9.2 Oral; 9.3 Intravenous; 9.4 Topical; 9.5 Others
10 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Treatment: 10.1 Overview; 10.2 Medication; 10.2.1 Corticosteroids; 10.2.1.1 Methylprednisolone; 10.2.1.2 Prednisolone; 10.2.2 Immunosuppressive; 10.2.2.1 Mycophenolate Mofetil (Mmf); 10.2.2.2 Methotrexate (Mtx); 10.2.2.3 Ibrutinib; 10.2.2.4 Belumosudil; 10.2.2.5 Ruxolitinib; 10.2.2.6 Antithymocyte Globulin (Atg); 10.2.2.7 Others; 10.2.3 Calcineurin Inhibitors; 10.2.3.1 Tacrolimus (Tac); 10.2.3.2 Cyclosporin (Csa); 10.2.3.3 Others; 10.2.4 Branded; 10.2.4.1 Rezurock; 10.2.4.2 Imbruvica; 10.2.4.3 Jakafi; 10.2.4.4 Orencia; 10.2.4.5 Others; 10.2.5 Generic; 10.3 Therapy
11 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Age: 11.1 Overview; 11.2 Adults; 11.3 Pediatric
12 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Gender: 12.1 Overview; 12.2 Female; 12.3 Male
13 Europe Graft-versus-host-disease (Gvhd) Treatment Market, By End User: 13.1 Overview; 13.2 Hospitals; 13.2.1 Public; 13.2.2 Private; 13.3 Transplant Centers; 13.4 Institutes; 13.5 Speciality Centers
14 Europe Graft-versus-host-disease (Gvhd) Treatment Market, By Distribution Channel: 14.1 Overview; 14.2 Direct Tender; 14.3 Retail Sales; 14.3.1 Hospital Pharmacy; 14.3.2 Retail Pharmacy; 14.3.3 Online Pharmacy; 14.4 Others
15 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Region: 15.1 Europe; 15.1.1 Germany; 15.1.2 France; 15.1.3 Italy; 15.1.4 U.K.; 15.1.5 Spain; 15.1.6 Belgium; 15.1.7 Russia; 15.1.8 Switzerland; 15.1.9 Denmark; 15.1.10 Rest Of Europe
16 Europe Graft Versus Host Disease (Gvhd) Treatment Market: Company Landscape: 16.1 Company Share Analysis: Europe
17 Swot Analysis
18 Company Profiles: 18.1 Bristol-myers Squibb Company; 18.1.1 Company Snapshot; 18.1.2 Revenue Analysis; 18.1.3 Company Share Analysis; 18.1.4 Product Portfolio; 18.1.5 Recent Developments; 18.2 Abbvie Inc.; 18.2.1 Company Snapshot; 18.2.2 Revenue Analysis; 18.2.3 Company Share Analysis; 18.2.4 Product Portfolio; 18.2.5 Recent Developments; 18.3 Novartis Ag; 18.3.1 Company Snapshot; 18.3.2 Revenue Analysis; 18.3.3 Company Share Analysis; 18.3.4 Product Portfolio; 18.3.5 Recent Developments; 18.4 Janssen Europe Services, Llc; 18.4.1 Company Snapshot; 18.4.2 Revenue Analysis; 18.4.3 Company Share Analysis; 18.4.4 Product Portfolio; 18.4.5 Recent Developments; 18.5 Mallinckrodt; 18.5.1 Company Snapshot; 18.5.2 Revenue Analysis; 18.5.3 Company Share Analysis; 18.5.4 Product Portfolio; 18.5.5 Recent Developments; 18.6 Alkem Laboratories Ltd.; 18.6.1 Company Snapshot; 18.6.2 Revenue Analysis; 18.6.3 Product Portfolio; 18.6.4 Recent Development; 18.7 Astellas Pharma Inc.; 18.7.1 Company Snapshot; 18.7.2 Revenue Analysis; 18.7.3 Product Portfolio; 18.7.4 Recent Development; 18.8 Incyte.; 18.8.1 Company Snapshot; 18.8.2 Revenue Analysis; 18.8.3 Product Portfolio; 18.8.4 Recent Developments; 18.9 Sanofi; 18.9.1 Company Snapshot; 18.9.2 Revenue Analysis; 18.9.3 Product Portfolio; 18.9.4 Recent Developments
19 Questionnaire
20 Related Reports: Table 1 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Type, 2022-2031 (Usd Thousand); Table 2 Europe Chronic Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 3 Europe Chronic Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 4 Europe Corticosteroids In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 5 Europe Immunosuppressive In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 6 Europe Chronic Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 7 Europe Branded In Graft-versus-host Disease (Gvhd) Treatment Market, By Type, 2022-2031 (Usd Thousand); Table 8 Europe Acute Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 9 Europe Acute Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 10 Europe Corticosteroids In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 11 Europe Immunosuppressive In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 12 Europe Calcineurin Inhibitors In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 13 Europe Prophylactic In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 14 Europe Prophylactic In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 15 Europe Prophylactic In Graft-versus-host Disease (Gvhd) Treatment Market, By Drug Type, 2022-2031 (Usd Thousand); Table 16 Europe Branded In Graft-versus-host Disease (Gvhd) Treatment Market, By Type, 2022-2031 (Usd Thousand); Table 17 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Method Of Administration, 2022-2031 (Usd Thousand); Table 18 Europe Oral In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 19 Europe Intravenous In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 20 Europe Topical In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 21 Europe Others In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 22 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Treatment, 2022-2031 (Usd Thousand); Table 23 Europe Medication In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 24 Europe Medication In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 25 Europe Corticosteroids In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 26 Europe Immunosuppressive In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 27 Europe Calcineurin Inhibitors In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 28 Europe Medication In Graft-versus-host Disease (Gvhd) Treatment Market, By Drug Type, 2022-2031 (Usd Thousand); Table 29 Europe Branded In Graft-versus-host Disease (Gvhd) Treatment Market, By Drug Type, 2022-2031 (Usd Thousand); Table 30 Europe Therapy In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 31 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Age, 2022-2031 (Usd Thousand); Table 32 Europe Adults In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 33 Europe Pediatric In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 34 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Gender, 2022-2031 (Usd Thousand); Table 35 Europe Female In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 36 Europe Male In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 37 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By End User, 2022-2031 (Usd Thousand); Table 38 Lobal Hospitals In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 39 Europe Hospitals In Graft-versus-host Disease (Gvhd) Treatment Market, By End User, 2022-2031 (Usd Thousand); Table 40 Europe Transplant Centers In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 41 Europe Institutes In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 42 Europe Speciality Centers In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 43 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Distribution Channel, 2022-2031 (Usd Thousand); Table 44 Europe Direct Tender In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 45 Europe Retail Sales In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 46 Europe Retail Sales In Graft-versus-host Disease (Gvhd) Treatment Market, By Distribution Channel, 2022-2031 (Usd Thousand); Table 47 Europe Others In Graft-versus-host Disease (Gvhd) Treatment Market, By Region, 2022-2031 (Usd Thousand); Table 48 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Country, 2022-2031 (Usd Thousand); Table 49 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Treatment, 2022-2031 (Usd Thousand); Table 50 Europe Medication In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 51 Europe Corticosteroids In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 52 Europe Immunosuppressive In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 53 Europe Calcineurin Inhibitors In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 54 Europe Medication In Graft-versus-host Disease (Gvhd) Treatment Market, By Drug Type, 2022-2031 (Usd Thousand); Table 55 Europe Branded In Graft-versus-host Disease (Gvhd) Treatment Market, By Drug Type, 2022-2031 (Usd Thousand); Table 56 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Type, 2022-2031 (Usd Thousand); Table 57 Europe Chronic Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 58 Europe Corticosteroids Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 59 Europe Immunosuppressive In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 60 Europe Chronic Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Drug Type, 2022-2031 (Usd Thousand); Table 61 Europe Branded In Graft-versus-host Disease (Gvhd) Treatment Market, By Type, 2022-2031 (Usd Thousand); Table 62 Europe Acute Gvhd In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 63 Europe Corticosteroids In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 64 Europe Immunosuppressives In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 65 Europe Calcineurin Inhibitors In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 66 Europe Prophylactic In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 67 Europe Prophylactic In Graft-versus-host Disease (Gvhd) Treatment Market, By Drug Type, 2022-2031 (Usd Thousand); Table 68 Europe Branded In Graft-versus-host Disease (Gvhd) Treatment Market, By Type, 2022-2031 (Usd Thousand); Table 69 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Gender, 2022-2031 (Usd Thousand); Table 70 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Age, 2022-2031 (Usd Thousand); Table 71 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Method Of Administration, 2022-2031 (Usd Thousand); Table 72 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By End User, 2022-2031 (Usd Thousand); Table 73 Europe Hospitals In Graft-versus-host Disease (Gvhd) Treatment Market, By End User, 2022-2031 (Usd Thousand); Table 74 Europe Graft-versus-host Disease (Gvhd) Treatment Market, By Distribution Channel, 2022-2031 (Usd Thousand); Table 75 Europe Retail Sales In Graft-versus-host Disease (Gvhd) Treatment Market, By Distribution Channel, 2022-2031 (Usd Thousand); Table 76 Germany Graft-versus-host Disease (Gvhd) Treatment Market, By Treatment, 2022-2031 (Usd Thousand); Table 77 Germany Medication In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Table 78 Germany Corticosteroids In Graft-versus-host Disease (Gvhd) Treatment Market, By Drugs, 2022-2031 (Usd Thousand); Figure 1 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Segmentation; Figure 2 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Data Triangulation; Figure 3 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Droc Analysis; Figure 4 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Europe Vs Regional Market Analysis; Figure 5 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Company Research Analysis; Figure 6 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Interview Demographics; Figure 7 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Market Application Coverage Grid; Figure 8 Europe Graft-versus-host Disease (Gvhd) Treatment Market: DBMR Market Position Grid; Figure 9 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Vendor Share Analysis; Figure 10 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Segmentation; Figure 11 The Growing Number Of Stem Cell Transplantations Is Driving The Growth Of The Europe Graft-versus-host Disease (Gvhd) Treatment Market From 2024 To 2031; Figure 12 The Treatment Segment Is Expected To Account For The Largest Share Of The Europe Graft-versus-host Disease (Gvhd) Treatment Market In 2024 And 2031; Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The Europe Graft-versus-host Disease (Gvhd) Treatment Market; Figure 14 Europe Graft-versus-host-disease (Gvhd) Treatment Market: By Type 2023; Figure 15 Europe Graft-versus-host-disease (Gvhd) Treatment Market: By Type, 2024-2031 (Usd Thousand); Figure 16 Europe Graft-versus-host-disease (Gvhd) Treatment Market: By Type, Cagr (2024-2031); Figure 17 Europe Graft-versus-host-disease (Gvhd) Treatment Market By Type, Lifeline Curve; Figure 18 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Method Of Administration, 2023; Figure 19 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Method Of Administration, 2024-2031 (Usd Thousand); Figure 20 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Method Of Administration, Cagr (2024-2031); Figure 21 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Method Of Administration, Lifeline Curve; Figure 22 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Treatment, 2023; Figure 23 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Treatment, 2024-2031 (Usd Thousand); Figure 24 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Treatment, Cagr (2024-2031); Figure 25 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Treatment, Lifeline Curve; Figure 26 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Age, 2023; Figure 27 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Age, 2024-2031 (Usd Thousand); Figure 28 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Age, Cagr (2024-2031); Figure 29 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Age, Lifeline Curve; Figure 30 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Gender, 2023; Figure 31 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Gender, 2024-2031 (Usd Thousand); Figure 32 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Gender, Cagr (2024-2031); Figure 33 Europe Graft-versus-host Disease (Gvhd) Treatment Market : By Gender, Lifeline Curve; Figure 34 Europe Graft-versus-host-disease (Gvhd) Treatment Market: By End User 2023; Figure 35 Europe Graft-versus-host-disease (Gvhd) Treatment Market: By End User, 2024-2031 (Usd Thousand); Figure 36 Europe Graft-versus-host-disease (Gvhd) Treatment Market: End User, Cagr (2024-2031); Figure 37 Europe Graft-versus-host-disease (Gvhd) Treatment Market End User, Lifeline Curve; Figure 38 Europe Graft-versus-host-disease (Gvhd) Treatment Market: By Distribution Channel 2023; Figure 39 Europe Graft-versus-host-disease (Gvhd) Treatment Market: By Distribution Channel, 2024-2031 (Usd Thousand); Figure 40 Europe Graft-versus-host-disease (Gvhd) Treatment Market: Distribution Channel, Cagr (2024-2031); Figure 41 Europe Graft-versus-host-disease (Gvhd) Treatment Market Distribution Channel, Lifeline Curve; Figure 42 Europe Graft-versus-host Disease (Gvhd) Treatment Market: Snapshot (2023); Figure 43 Europe Graft Versus Host Disease (Gvhd) Treatment Market: Company Share 2023 (%)